Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abivertinib Safety and Efficacy in ADME Participants
NCT03053219Phase 1Completed
- Sponsor
- ACEA Therapeutics
- Start
- Nov 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abivertinib in non-small cell lung cancer (NSCLC), sponsored by ACEA Therapeutics. Primary endpoint: Objective Response Rate up to 11 months. Started Nov 2016; status: completed.
02
Drugs
abivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03053219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053219.